

Spinal Muscular Atrophy: Epidemiology Forecasting Intelligence

https://marketpublishers.com/r/SC42CC315ACEN.html

Date: February 2019

Pages: 50

Price: US\$ 2,500.00 (Single User License)

ID: SC42CC315ACEN

Abstracts

CmaxInsight's "Spinal Muscular Atrophy-Epidemiology Forecasting Intelligence" report provides a comprehensive analysis of the Spinal Muscular Atrophy epidemiology, providing the historical, current, and forecasted data for the United States, European Union 5 (EU5- Germany, Spain, Italy, France and United Kingdom) and Japan during the period from 2018-2028.

Our epidemiology services include:

Incidence and prevalence

Diagnosis rate, treatment rate and mortality patterns

Epidemiology-based forecasting and disease trends

Size of different patient segments in a disease area

Population based: disease occurrence, co-morbidities and treatment patterns

Geographic - Regional - Ethnic differences

Along with the epidemiological data, the report also includes:

Disease overview, causes, symptoms, classification, risk factor, pathophysiology, diagnosis and treatment



Patient treatment journey

Treatment algorithm and guidelines

Assesses the disease risk and burden

Highlights the unmet needs

Market driver and barrier

Growth opportunities and market trend analysis

Methodology

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house Epidemiology Forecast model analysis by a team of industry experts.

To generate accurate patient population estimates, utilizes a combination of several world class sources that deliver the most up to date information from patient registries, clinical trials and epidemiology studies.

All of the sources used to generate the data and analysis have been identified in the report.

Note: Systematic review of the epidemiological literature is also provided for full transparency into research and methods. This report can be delivered to the clients within 4-5 business days.



Contents

- 1. REPORT INTRODUCTION
- 2. SPINAL MUSCULAR ATROPHY EPIDEMIOLOGY OVERVIEW AT A GLANCE
- 3. MARKET SHARE DISTRIBUTION OF SPINAL MUSCULAR ATROPHY
- 4. DISEASE BACKGROUND AND OVERVIEW: SPINAL MUSCULAR ATROPHY
- 4.1. Introduction
- 4.2. Signs and Symptoms
- 4.3. Etiology
- 4.4. Risk Factors
- 4.5. Pathophysiology
- 4.6. Diagnostic Landscape
- 4.6.1. Diagnostic Practices
- 4.6.2. Diagnostic Criteria
- 4.6.3. Diagnostic Recommendations
- 4.7. Treatment Landscape
 - 4.7.1. Current Treatment Practices
 - 4.7.2. Treatment Algorithm
 - 4.7.3. Treatment Recommendations

5. SPINAL MUSCULAR ATROPHY EPIDEMIOLOGY

- 5.1. Key Findings
- 5.2. Assumptions & Rationale
- 5.3. 7MM Epidemiology

6. EPIDEMIOLOGY OF SPINAL MUSCULAR ATROPHY BY COUNTRIES

7. UNITED STATES

- 7.1. Assumptions and Rationale
- 7.2. Prevalent/Incident Cases of Spinal Muscular Atrophy
- 7.3. Sub-Type Specific cases of Spinal Muscular Atrophy*
- 7.4. Sex- Specific Cases of Spinal Muscular Atrophy*
- 7.5. Diagnosed Cases of Spinal Muscular Atrophy



7.6. Treated Cases of Spinal Muscular Atrophy

8. EU5

8.1	. (Ge	rm	an	۱۷
-----	-----	----	----	----	----

- 8.1.1. Assumptions and Rationale
- 8.1.2. Prevalent/Incident Cases of Spinal Muscular Atrophy
- 8.1.3. Sub-Type Specific cases of Spinal Muscular Atrophy*
- 8.1.4. Sex- Specific Cases of Spinal Muscular Atrophy*
- 8.1.5. Diagnosed Cases of Spinal Muscular Atrophy
- 8.1.6. Treated Cases of Spinal Muscular Atrophy

8.2. France

- 8.2.1. Assumptions and Rationale
- 8.2.2. Prevalent/Incident Cases of Spinal Muscular Atrophy
- 8.2.3. Sub-Type Specific cases of Spinal Muscular Atrophy*
- 8.2.4. Sex- Specific Cases of Spinal Muscular Atrophy*
- 8.2.5. Diagnosed Cases of Spinal Muscular Atrophy
- 8.2.6. Treated Cases of Spinal Muscular Atrophy

8.3. United Kingdom

- 8.3.1. Assumptions and Rationale
- 8.3.2. Prevalent/Incident Cases of Spinal Muscular Atrophy
- 8.3.3. Sub-Type Specific cases of Spinal Muscular Atrophy*
- 8.3.4. Sex- Specific Cases of Spinal Muscular Atrophy*
- 8.3.5. Diagnosed Cases of Spinal Muscular Atrophy
- 8.3.6. Treated Cases of Spinal Muscular Atrophy

8.4. Spain

- 8.4.1. Assumptions and Rationale
- 8.4.2. Prevalent/Incident Cases of Spinal Muscular Atrophy
- 8.4.3. Sub-Type Specific cases of Spinal Muscular Atrophy*
- 8.4.4. Sex- Specific Cases of Spinal Muscular Atrophy*
- 8.4.5. Diagnosed Cases of Spinal Muscular Atrophy
- 8.4.6. Treated Cases of Spinal Muscular Atrophy

8.5. Italy

- 8.5.1. Assumptions and Rationale
- 8.5.2. Prevalent/Incident Cases of Spinal Muscular Atrophy
- 8.5.3. Sub-Type Specific cases of Spinal Muscular Atrophy*
- 8.5.4. Sex- Specific Cases of Spinal Muscular Atrophy*
- 8.5.5. Diagnosed Cases of Spinal Muscular Atrophy
- 8.5.6. Treated Cases of Spinal Muscular Atrophy



9. JAPAN

- 9.1. Assumptions and Rationale
- 9.2. Prevalent/Incident Cases of Spinal Muscular Atrophy
- 9.3. Sub-Type Specific cases of Spinal Muscular Atrophy*
- 9.4. Sex- Specific Cases of Spinal Muscular Atrophy*
- 9.5. Diagnosed Cases of Spinal Muscular Atrophy
- 9.6. Treated Cases of Spinal Muscular Atrophy

10. UNMET NEEDS

Appendix Report Methodology Sources Used Disclaimer

About CmaxInsight

*Indication Specific

Note: Certain sections of the table of contents would vary according to the availability of information.



List Of Tables

LIST OF TABLES

- Table 1: Total Prevalent/Incident Cases of the Spinal Muscular Atrophy in 7MM
- Table 2: Total Prevalent/Incident Cases of the Spinal Muscular Atrophy in 7MM by Countries
- Table 3: Prevalent/Incident Cases of the Spinal Muscular Atrophy in United States
- Table 4: Sub-Type Specific Cases of the Spinal Muscular Atrophy in United States*
- Table 5: Sex- Specific Cases of the Spinal Muscular Atrophy in United States*
- Table 6: Diagnosed Cases of the Spinal Muscular Atrophy in United States
- Table 7: Treated Cases of the Spinal Muscular Atrophy in United States
- Table 8: Prevalent/Incident Cases of the Spinal Muscular Atrophy in Germany
- Table 9: Sub-Type Specific Cases of the Spinal Muscular Atrophy in Germany*
- Table 10: Sex- Specific Cases of the Spinal Muscular Atrophy in Germany*
- Table 11: Diagnosed Cases of the Spinal Muscular Atrophy in Germany
- Table 12: Treated Cases of the Spinal Muscular Atrophy in Germany
- Table 13: Prevalent/Incident Cases of the Spinal Muscular Atrophy in France
- Table 14: Sub-Type Specific Cases of the Spinal Muscular Atrophy in France*
- Table 15: Sex- Specific Cases of the Spinal Muscular Atrophy in France*
- Table 16: Diagnosed Cases of the Spinal Muscular Atrophy in France
- Table 17: Treated Cases of the Spinal Muscular Atrophy in France
- Table 18: Prevalent/Incident Cases of the Spinal Muscular Atrophy in Italy
- Table 19: Sub-Type Specific Cases of the Spinal Muscular Atrophy in Italy*
- Table 20: Sex- Specific Cases of the Spinal Muscular Atrophy in Italy*
- Table 21: Diagnosed Cases of the Spinal Muscular Atrophy in Italy
- Table 22: Treated Cases of the Spinal Muscular Atrophy in Italy
- Table 23: Prevalent/Incident Cases of the Spinal Muscular Atrophy in Spain
- Table 24: Sub-Type Specific Cases of the Spinal Muscular Atrophy in Spain*
- Table 25: Sex- Specific Cases of the Spinal Muscular Atrophy in Spain*
- Table 26: Diagnosed Cases of the Spinal Muscular Atrophy in Spain
- Table 27: Treated Cases of the Spinal Muscular Atrophy in Spain
- Table 28: Prevalent/Incident Cases of the Spinal Muscular Atrophy in UK
- Table 29: Sub-Type Specific Cases of the Spinal Muscular Atrophy in UK*
- Table 30: Sex- Specific Cases of the Spinal Muscular Atrophy in UK*
- Table 31: Diagnosed Cases of the Spinal Muscular Atrophy in UK
- Table 32: Treated Cases of the Spinal Muscular Atrophy in UK
- Table 33: Prevalent/Incident Cases of the Spinal Muscular Atrophy in Japan
- Table 34: Sub-Type Specific Cases of the Spinal Muscular Atrophy in Japan*



Table 35: Sex- Specific Cases of the Spinal Muscular Atrophy in Japan*

Table 36: Diagnosed Cases of the Spinal Muscular Atrophy in Japan

Table 37: Treated Cases of the Spinal Muscular Atrophy in Japan

*Indication Specific



List Of Figures

LIST OF FIGURES

Figure 1: Total Prevalent/Incident Cases of the Spinal Muscular Atrophy in 7MM

Figure 2: Total Prevalent/Incident Cases of the Spinal Muscular Atrophy in 7MM by Countries

Figure 3: Prevalent/Incident Cases of the Spinal Muscular Atrophy in United States

Figure 4: Sub-Type Specific Cases of the Spinal Muscular Atrophy in United States*

Figure 5: Sex- Specific Cases of the Spinal Muscular Atrophy in United States*

Figure 6: Diagnosed Cases of the Spinal Muscular Atrophy in United States

Figure 7: Treated Cases of the Spinal Muscular Atrophy in United States

Figure 8: Prevalent/Incident Cases of the Spinal Muscular Atrophy in Germany

Figure 9: Sub-Type Specific Cases of the Spinal Muscular Atrophy in Germany*

Figure 10: Sex- Specific Cases of the Spinal Muscular Atrophy in Germany*

Figure 11: Diagnosed Cases of the Spinal Muscular Atrophy in Germany

Figure 12: Treated Cases of the Spinal Muscular Atrophy in Germany

Figure 13: Prevalent/Incident Cases of the Spinal Muscular Atrophy in France

Figure 14: Sub-Type Specific Cases of the Spinal Muscular Atrophy in France*

Figure 15: Sex- Specific Cases of the Spinal Muscular Atrophy in France*

Figure 16: Diagnosed Cases of the Spinal Muscular Atrophy in France

Figure 17: Treated Cases of the Spinal Muscular Atrophy in United France

Figure 18: Prevalent/Incident Cases of the Spinal Muscular Atrophy in Italy

Figure 19: Sub-Type Specific Cases of the Spinal Muscular Atrophy in Italy*

Figure 20: Sex- Specific Cases of the Spinal Muscular Atrophy in Italy*

Figure 21: Diagnosed Cases of the Spinal Muscular Atrophy in Italy

Figure 22: Treated Cases of the Spinal Muscular Atrophy in Italy

Figure 23: Prevalent/Incident Cases of the Spinal Muscular Atrophy in Spain

Figure 24: Sub-Type Specific Cases of the Spinal Muscular Atrophy in Spain*

Figure 25: Sex- Specific Cases of the Spinal Muscular Atrophy in Spain*

Figure 26: Diagnosed Cases of the Spinal Muscular Atrophy in Spain

Figure 27: Treated Cases of the Spinal Muscular Atrophy in Spain

Figure 28: Prevalent/Incident Cases of the Spinal Muscular Atrophy in UK

Figure 29: Sub-Type Specific Cases of the Spinal Muscular Atrophy in UK*

Figure 30: Sex- Specific Cases of the Spinal Muscular Atrophy in UK*

Figure 31: Diagnosed Cases of the Spinal Muscular Atrophy in UK

Figure 32: Treated Cases of the Spinal Muscular Atrophy in UK

Figure 33: Prevalent/Incident Cases of the Spinal Muscular Atrophy in Japan

Figure 34: Sub-Type Specific Cases of the Spinal Muscular Atrophy in Japan*



Figure 35: Sex- Specific Cases of the Spinal Muscular Atrophy in Japan*

Figure 36: Diagnosed Cases of the Spinal Muscular Atrophy in Japan

Figure 37: Treated Cases of the Spinal Muscular Atrophy in Japan

*Indication Specific



I would like to order

Product name: Spinal Muscular Atrophy: Epidemiology Forecasting Intelligence

Product link: https://marketpublishers.com/r/SC42CC315ACEN.html

Price: US\$ 2,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/SC42CC315ACEN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:					
Last name:					
Email:					
Company:					
Address:					
City:					
Zip code:					
Country:					
Tel:					
Fax:					
Your message:					
	**All fields are required				
	Custumer signature				

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

& Conditions at https://marketpublishers.com/docs/terms.html

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms